- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
DelMar Pharmaceuticals Announces Upcoming Scientific Conference Presentations
VANCOUVER, British Columbia and MENLO PARK, Calif., Oct. 13, 2016 /PRNewswire/ — DelMar Pharmaceuticals (NASDAQ:DMPI), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that the Company and its research collaborators have been invited to present data regarding the progress of VAL-083 at the following upcoming peer-reviewed scientific conferences:
VANCOUVER, British Columbia and MENLO PARK, Calif., Oct. 13, 2016 /PRNewswire/ — DelMar Pharmaceuticals (NASDAQ:DMPI), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that the Company and its research collaborators have been invited to present data regarding the progress of VAL-083 at the following upcoming peer-reviewed scientific conferences:
- European Association of NeuroOncology (EANO) Annual Meeting (Heidelberg, GermanyOct. 12 – 16, 2016);
- AACR DNA Repair: Tumor Development and Therapeutic Response (Montreal, CanadaNov. 2 – 5, 2016);
- AACR New Horizons in Cancer Research: Delivering Cures through Cancer Research (Shanghai, ChinaNov. 2 – 4, 2016);
- Society for NeuroOncology Annual Meeting and CNS Anti-Cancer Drug Development Conference (Scottsdale, USANov. 16 – 20, 2016);
- EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium (Munich, GermanyNov 29 – Dec. 2, 2016); and
- IASLC 17th World Congress on Lung Cancer (Vienna, AustriaDec. 4 – 7, 2016).
“We are pleased to accept these invitations to present new data at these prestigious peer-reviewed meetings,” said Jeffrey Bacha, DelMar’s chairman & CEO. “Data presented at these global meetings will highlight the continued success of our strategy to leverage historical clinical validation from prior NCI-sponsored research with a modern understanding of VAL-083’s unique anti-cancer mechanism.”
VAL-083 is a “first-in-class,” small-molecule chemotherapeutic. In more than 40 Phase I and II clinical studies sponsored by the U.S. National Cancer Institute, VAL-083 demonstrated clinical activity against a range of cancers including lung, brain, cervical, ovarian tumors and leukemia both as a single-agent and in combination with other treatments.
“Taken together, these data support VAL-083’s potential to address unmet medical needs in major cancer indications for patients whose tumors have failed, or exhibit features that make them resistant or unlikely to respond to, current standard-of-care chemotherapy,” added Mr. Bacha.
Connect with DelMar Pharmaceuticals (NASDAQ:DMPI) to receive an Investor Presentation.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.